This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lu, J. Articles by Ching, L.-M. Search for Related Content PubMed PubMed Citation Articles by Lu, J. Articles by Ching, L.-M.

Thalidomide Metabolites in Mice and Patients with Multiple Myeloma¹

Auckland Cancer Society Research Centre [J. L., B. D. P., P. K., B. C. B., L-M. C.] and Department of Molecular Medicine and Pathology [P. B.], Faculty of Medical and Health Sciences, The University of Auckland, Auckland 92019, New Zealand, and Celgene Corporation, Warren, New Jersey [G. M.]

Purpose:This research examines the profile of metabolites of thalidomide that are formed in refractory multiple myeloma patients undergoing thalidomide therapy in comparison with those that are detected in healthy mice.

Experimental Design: Urine or plasma samples from patients during thalidomide therapy (100–400 mg daily), or from mice treated i.p. (100 mg/kg) or p.o. with thalidomide (50 mg/kg) were analyzed using liquid chromatography-mass spectrometry. Metabolites in each of the peaks observed in the UV- and mass spectrometry-detected high-performance liquid chromatography traces were identified by comparison of retention times and spectra with those of authentic standards.

Results: Plasma and urine samples from mice 4 h after treatment with thalidomide contained eight major metabolites formed by hydroxylation and/or hydrolysis of thalidomide. In contrast, urine samples from seven multiple myeloma patients at steady state levels of thalidomide therapy showed the presence of only three hydrolysis breakdown products and no hydroxylated metabolites.

Conclusions: Our results show that thalidomide metabolite profiles in multiple myeloma patients differ considerably from those in mice. The lack of measurable hydroxylated metabolites in urine and in 1 case plasma of these patients suggests that such metabolites are not responsible for the therapeutic effects of thalidomide in multiple myeloma. We suggest that thalidomide may act directly, down-regulating growth factors essential for multiple myeloma growth.

This article has been cited by other articles:

				S. K. Teo, K. H. Denny, D. I. Stirling, S. D. Thomas, S. Morseth, and A. M. Hoberman Effects of Thalidomide on Developmental, Peri- and Postnatal Function in Female New Zealand White Rabbits and Offspring Toxicol. Sci., October 1, 2004; 81(2): 379 - 389. [Abstract] [Full Text] [PDF]

				F. Chung, J. Lu, B. D. Palmer, P. Kestell, P. Browett, B. C. Baguley, M. Tingle, and L.-M. Ching Thalidomide Pharmacokinetics and Metabolite Formation in Mice, Rabbits, and Multiple Myeloma Patients Clin. Cancer Res., September 1, 2004; 10(17): 5949 - 5956. [Abstract] [Full Text] [PDF]

				J. Lu, N. Helsby, B. D. Palmer, M. Tingle, B. C. Baguley, P. Kestell, and L.-M. Ching Metabolism of Thalidomide in Liver Microsomes of Mice, Rabbits, and Humans J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 571 - 577. [Abstract] [Full Text] [PDF]

				S. Kumar, T. E. Witzig, and S. V. Rajkumar Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies J. Clin. Oncol., June 15, 2004; 22(12): 2477 - 2488. [Abstract] [Full Text] [PDF]

				M. A. Dimopoulos, A. Anagnostopoulos, and D. Weber Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives J. Clin. Oncol., December 1, 2003; 21(23): 4444 - 4454. [Abstract] [Full Text] [PDF]

				S. Zhou Correspondence re: J. Lu et al., Thalidomide Metabolites in Mice and Patients with Multiple Myeloma. Clin. Cancer Res., 9: 1680-1688, 2003. Clin. Cancer Res., November 1, 2003; 9(14): 5429 - 5429. [Full Text] [PDF]